Hsp90 Inhibitor Can Inhibit UV Carcinogenesis  by Katiyar, Santosh K.
Slominski AT, Kleszczynski K, Semak I et al. (2014)
Local melatoninergic system as the
protector of skin integrity. Int J Mol Sci 15:
17705–32
Slominski AT, Zmijewski MA, Skobowiat C et al.
(2012) Sensing the environment: regulation of
local and global homeostasis by the skin’s
neuroendocrine system. Adv Anat Embryol
Cell Biol 212:1–115
Slominski AT, Zmijewski MA, Zbytek B et al.
(2013) Key role of CRF in the skin stress
response system. Endocr Rev 34:827–84
Hsp90 Inhibitor Can Inhibit
UV Carcinogenesis
Santosh K. Katiyar1,2
Extensive exposure to solar UVR is a well-recognized etiologic factor for
cutaneous non-melanoma skin cancer. In this issue of the Journal, Singh et al.
show that topical treatment of the skin with 17-[allylamino]-17-demethoxygelda-
namycin (17AAG), a heat-shock protein 90 (Hsp90) inhibitor, prevents UVR-
induced squamous cell carcinomas (SCCs) in mice. The inhibitory effect of 17AAG
on SCC was associated with the inhibition of the UVR-induced (i) hyperplastic
response, (ii) Hsp90b-PKCe interaction, and (iii) pStat3 and pAkt expression in
mouse skin.
Journal of Investigative Dermatology (2015) 135, 945–947; doi:10.1038/jid.2014.504
Epidemiological, clinical, and labora-
tory studies have implicated solar UVR
in tumor initiation, tumor promotion,
and complete carcinogenesis. Excessive
exposure to UVR can lead to the initia-
tion and development of several skin
disorders/diseases and increase the risk
of melanoma and non-melanoma skin
cancers (Baliga and Katiyar, 2006). UVR
exposure induces inflammatory respon-
ses, oxidative stress, immunosuppres-
sion, DNA damage, and gene mut-
ations. Individually, each of these
effects can contribute to the risk of
skin cancers, and collectively they
heighten the risk considerably.
Multiple molecular targets and
biomarkers have been identified,
which have significant roles in skin
diseases. Efforts have been made to
develop new and more effec-
tive strategies for the treatment and/or
prevention of these skin diseases. For
more than two decades, efforts have
been concentrated on screening and
testing the chemopreventive effects
of natural plant products or phyto-
chemicals using various animal models.
Phytochemicals, including dietary plant
products, offer promising options for the
development of more effective chemo-
preventive or chemotherapeutic strate-
gies for cancers of different organs
including the skin. These alternative
strategies are based upon the specific
characteristics of the individual phyto-
chemicals, such as their anti-inflam-
matory, antioxidant, DNA repair activi-
ties and their ability to stimulate the
immune system. In line with these
investigations and strategies, green tea
polyphenols, grape seed proantho-
cyanidins, and silymarin have been
studied extensively, and these phyto-
chemicals have shown significant anti-
skin carcinogenesis effects both in
in vitro and in vivo in animal models
(Baliga and Katiyar, 2006; Nichols and
Katiyar, 2010). Multiple molecular tar-
gets, including inflammatory mediators,
oxidative stress, DNA damage and
repair, and immunological responses,
have been identified that are respon-
sible for the prevention of UVR-induced
skin carcinogenesis by these phyto-
chemicals.
The research laboratory of Dr Verma
and colleagues reported the activation
of protein kinase Ce (PKCe), a novel
PKC isoform, in UV-exposed skin and
demonstrated that PKCe activation
mediates UVR-induced tumor necrosis
factor-a release, which is linked to the
development of squamous cell carcino-
mas (SCCs; Wheeler et al., 2004). PKCe
is among the six PKC isoforms (a, d, e, m,
x, and Z) that are expressed in both
human and mouse skin. PKCe over-
expression decreased the latency while
increasing the incidence and multi-
plicity of the SCCs in PKCe transgenic
mice (Wheelar et al., 2004). It has been
reported that the possible mechanisms
by which PKCe mediates susceptibility
to SCC induction include PKCe-medi-
ated anti-apoptotic and cell survival
signals (Aziz et al., 2007). The PKCe-
mediated cell survival signal may
involve interaction of PKCe with Stat3,
which also has been linked to the
induction of skin cancer (Goetz et al.,
2005).
In this issue, Singh et al. (2015) have
shown that UVR exposure increases the
interaction of PKCe with heat-shock
protein 90b (Hsp90b) and that this
interaction may have an important role
in UVR-induced SCCs. The chaperone
Hsp90 mediates the maturation and
stabilization of PKCe as a client protein
(Gould et al., 2009) and also has a
significant role in cell transformation,
proliferation, and cell survival (Miyata
et al., 2013). Hsp90 is of considerable
interest as an oncogenic target as tumor
cells and oncogenic proteins are heavily
dependent on its activity (Soti et al.,
2005). By inhibiting Hsp90 one can
target a large number of downstream
proteins and thereby attack the neo-
plastic process at several points as
illustrated in Figure 1. Consequently,
several Hsp90 inhibitors have been
developed and are being evaluated for
treatment of various human cancers
(Cullinan and Whitesell, 2006). Gelda-
namycin, the first Hsp90 inhibitor to be
tested in a clinical trial, failed because
of hepatotoxicity. Second-generation
derivatives, such as 17-[allylamino]-17-
See related article on pg 1098
1Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, USA and
2Department of Dermatology, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, USA
Correspondence: Santosh K. Katiyar, Department of Dermatology, University of Alabama at Birmingham,
Birmingham, Alabama 35294, USA. E-mail: skatiyar@uab.edu
COMMENTARY
www.jidonline.org 945
demethoxygeldanamycin (17AAG), do
not cause liver toxicity and currently
are being evaluated in phase II clinical
trials (Heath et al., 2008; Pacey et al.,
2012). A large number of clinical trials
are exploring the use of 17AAG and
other Hsp90 inhibitors in various
cancers including melanoma (Cullinan
and Whitesell, 2006); however, Hsp90
inhibitors have never been investigated
in terms of the prevention and treatment
of UVR-induced SCC. As many of the
molecular targets of UVR-induced skin
carcinogenesis are dependent on Hsp90
for maturity, stability, and activity, Singh
and colleagues formulated the hypo-
thesis that treatment of Hsp90 inhibitor
in conjunction with UVR exposure
will prevent development of cutaneous
SCCs. Singh and colleagues demon-
strate for the first time that topical
treatment with the Hsp90 inhibitor,
17AAG, is nontoxic and is effective in
prevention of UVR-induced SCC deve-
lopment in mice in terms of inhibition of
tumor incidence and tumor multiplicity
and an increased latency period before
first tumor appearance. The results
concerning tumor development were
verified in three mouse models: SKH-1
hairless, wild-type FVB, and PKCe over-
expressing transgenic FVB mice. 17AAG
is an ATP antagonist and inhibits Hsp90
and ATPase activity. Inhibition of Hsp90
ATPase activity by 17AAG affects the
maturity and stability of its client
proteins including PKCe. Interestingly,
Singh and colleagues found that UVR
exposure of mouse skin resulted in
increased expression of PKCe, possibly
due to its increased synthesis. They also
demonstrate that topical application of
17AAG to mouse skin inhibited UVR-
induced Hsp90b-PKCe interaction, as
well as expression levels of pStat3 and
pAkt. These findings are consistent with
the requirement for the sequential phos-
phorylation of newly synthesized PKC
and its binding to Hsp90, which is a
required step in its maturation and
stability (Gould et al., 2009).
Clinical Implications
 Topical application of the heat-shock protein 90 (Hsp90) inhibitor 17-
[allylamino]-17-demethoxygeldanamycin (17AAG) significantly inhibits
UVR-induced cutaneous squamous cell carcinoma (SCC) development in
mice.
 Therapeutic blockade of the interaction between protein kinase Ce and
Hsp90 by 17AAG is a promising approach to prevent UVR-induced skin
carcinogenesis.
 17AAG might be supplemented with the use of sunscreens to reduce UVR-
induced adverse effects, such as hyperplastic skin diseases (e.g., actinic
keratosis) and/or photoaging of the skin.
Figure 1. Schematic illustration showing the molecular targets of 17-[allylamino]-17-demethoxygeldanamycin (17AAG), an inhibitor of heat-shock protein 90
(Hsp90), in UVR-induced skin carcinogenesis. Skin exposure to UVR induces the activation of multiple signal transduction pathways culminating in activation of
transcription factors (AP1, NF-kB, Stat3, and so on) and constitutive expression of genes (e.g., cytokines, COX-2, cyclin D1, Survivin, and so on) essential for
squamous cell carcinomas (SCCs) development. The molecular targets in UVR-induced skin carcinogenesis require Hsp90 for their maturity, stability, and activity.
17AAG inhibits UVR-induced SCC via inhibition of Hsp90 ATPase activity essential for the stability of UVR-activated signal transduction pathways.
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In this issue, Singh et al. (2015) also
report the effects of 17AAG on the
biomarkers of chronic UVR-induced
photoaging of the skin. Overexpression
of matrix metalloproteinases (MMPs) in
UV-exposed skin has been implicated in
the wrinkling of the skin or premature
aging of the skin that is known as
photoaging of the skin. Topical treat-
ment of the SKH-1 hairless mouse skin
with 17AAG before and after UVR
exposure resulted in decreased levels
of MMP-2 and MMP-9 proteins as com-
pared with the mouse skin, which was
not treated with 17AAG but exposed to
UVR. These results suggest that 17AAG
treatment may protect the skin from
photoaging through inhibition of
MMPs.
Singh et al. (this issue, 2015) have
demonstrated convincingly that 17AAG
has the ability to inhibit UVR-induced
SCC development and also inhibits
selected biomarkers of photoaging of
the skin. However, UVR-induced deve-
lopment of SCCs accompanies expres-
sion and activation of several oncogenic
signal transduction pathways, as sum-
marized in Figure 1. Thus, more
rigorous, mechanism-based studies are
warranted to establish the molecular
mechanisms underlying prevention of
UVR-induced SCCs in the skin by
17AAG. Further studies may reveal a
broader mechanism of action of Hsp90
inhibitor, 17AAG.
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Focus on Early Detection to Reduce
Melanoma Deaths
Alan C. Geller1, Susan M. Swetter2 and Martin A. Weinstock3
Thin fatal melanomas are a relatively new clinical and public health concern,
representing an estimated 20% of melanoma deaths. Understanding this pheno-
menon will require a multi-pronged approach, including in-depth investigation of
its behavioral and biological underpinnings. As we proceed with relevant studies,
the benefits in lives saved will grow via early detection.
Journal of Investigative Dermatology (2015) 135, 947–949; doi:10.1038/jid.2014.534
Whiteman and colleagues (this issue,
2014) contribute to our understanding
and management of melanoma from
the public health perspective by reinfor-
cing the importance of measures that
reduce the number of deaths from both
thin and thick melanomas (Whiteman
et al., 2014). We wish to underscore
three key points: (a) the comprehensive
nature of our quest to reduce deaths
from melanoma, (b) the need to under-
stand the nature of thin melanomas
that are ultimately fatal, and (c) the
focus on early detection as the highest
priority in the effort to reduce
melanoma deaths.
Mortality rates in the USA and else-
where are declining for four of the five
cancers most amenable to early detec-
tion. Cancers of the breast, cervix,
colon, and prostate have demonstrated
mortality reductions, ranging from 20
to 60% over the past 25 years
(www.cdc.gov/nchs). However, if cur-
rent trends in cancer death rates con-
tinue, melanoma will be the only cancer
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